candezek combi 16 mg + 10 mg kapsułki twarde
adamed pharma s.a. - candesartanum cilexetili + amlodipinum - kapsułki twarde - 16 mg + 10 mg
candezek combi 16 mg + 5 mg kapsułki twarde
adamed pharma s.a. - candesartanum cilexetili + amlodipini besilas - kapsułki twarde - 16 mg + 5 mg
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - wieprzowy - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
imatinib aurovitas 400 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - imatinibum - tabletki powlekane - 400 mg
azithromycin aurovitas 250 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - azithromycinum dihydricum - tabletki powlekane - 250 mg
azithromycin aurovitas 500 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - azithromycinum dihydricum - tabletki powlekane - 500 mg
alocutan forte 50 mg/ml aerozol na skórę, roztwór
sun-farm sp. z o.o. - minoxidilum - aerozol na skórę, roztwór - 50 mg/ml
alocutan 20 mg aerozol na skórę, roztwór
sun-farm sp. z o.o. - minoxidilum - aerozol na skórę, roztwór - 20 mg
imatinib aurovitas 100 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - imatinibum - tabletki powlekane - 100 mg
crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - leki stosowane w leczeniu chorób kości - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.